Amylyx Pharmaceuticals nabs $30M for ALS, Alzheimer's work

After posting positive data that showed it could help slow down amyotrophic lateral sclerosis (ALS), Amylyx Pharmaceuticals has been given a $30 million boost.

Its leading candidate, AMX0035, is being tested in degenerative ALS and Alzheimer’s disease, two very tough targets with a long history of failures.